Artivion (NYSE:AORT) Trading Up 7% – What’s Next?

Artivion, Inc. (NYSE:AORT) shares were up 7% on Thursday . The stock traded as high as $26.01 and last traded at $26.0150. 396,020 shares traded hands during trading, a decline of 31% from the average session volume of 577,641 shares. The stock had previously closed at $24.31.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on AORT. Canaccord Genuity Group reiterated a “buy” rating and set a $36.00 price target on shares of Artivion in a research report on Tuesday, June 16th. Weiss Ratings cut Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, June 8th. Stifel Nicolaus set a $45.00 price objective on Artivion in a research note on Monday, June 1st. Wall Street Zen cut Artivion from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, Needham & Company LLC decreased their target price on Artivion from $58.00 to $44.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $44.17.

Artivion Stock Up 5.9%

The firm’s 50-day moving average price is $22.66 and its 200 day moving average price is $33.23. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of 107.17 and a beta of 1.26. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.86 and a quick ratio of 2.80.

Insider Transactions at Artivion

In related news, SVP Andrew M. Green sold 44,001 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total value of $910,820.70. Following the sale, the senior vice president owned 60,259 shares of the company’s stock, valued at approximately $1,247,361.30. This represents a 42.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.30% of the company’s stock.

Institutional Trading of Artivion

A number of large investors have recently made changes to their positions in AORT. Royal Bank of Canada increased its position in Artivion by 107.0% during the 1st quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock worth $952,000 after purchasing an additional 20,010 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Artivion by 8.8% during the first quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock worth $862,000 after buying an additional 2,823 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Artivion by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock valued at $580,000 after buying an additional 1,032 shares during the last quarter. Creative Planning raised its position in shares of Artivion by 5.6% in the second quarter. Creative Planning now owns 14,272 shares of the company’s stock valued at $444,000 after buying an additional 753 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in shares of Artivion by 40.8% during the second quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock valued at $14,960,000 after buying an additional 139,370 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.